Objective: Indirect pharmacological evidence suggests that myocardial protection conferred by ischemic preconditioning in rabbit myocardium is mediated through the translocation of protein kinase C (PKC). To test this hypothesis, we performed direct biochemical measurements of subcelhrlar distribution of PKC in rabbit hearts. Methods: Two protocols were utilized. In Protocol I the preconditioned group (PC) underwent two 5-rein episodes of brief coronary artery occlusion each followed by 5 min of reperfusion, while the control group consisted of time-matched, sham-operated (non-ischemic) animals (SO). Tissue samples were homogenized and cytosolic and particulate fractions were obtained by ultracentrifugation. In Protocol H one group of rabbits received ischemic preconditioning as in Protocol I followed by 10 min of sustained ischemia (PC + IS); a second control group was subjected to 10 min of sustained ischemia (1S); and the third group was time-matched, sham-operated (non-ischemic) animals (S0). Homogenized tissue samples were separated into cytosolic, nuclear and membrane fractions. Results: In Protocol1,no differencesin the subcellulardistributionof PKC betweenthe SO and PC groups were observed. In Protocol II, when samples were obtained at 10 min of sustained ischemia, no changes in the subcellular distribution of PKC wereobservedbetweenSO,IS andPC + IS groups.Conclusion: Our results indicate that translocation of protein kinase C is not an important mediator of ischemic preconditioning in the rabbit ischemia model.
Introduction
Although the exact mechanism of ischemic preconditioning remains obscure, several reports indicate that this phenomenon may be a form of receptor-mediated cardiac protection. In the rabbit model it has been suggested that adenosine, released during preconditioning episodes of ischemia/reperfusion, activates A ,-adenosine receptors and, through a pertussis-toxin-sensitive G-protein stimulates phospholipase C activity. This results in phospholipid hydrolysis with subsequent generation of inositol 1,4,5-tnsphosphate (InsPj) and diacylglycerol. The latter results in protein kinase C (PKC) translocation from the cytosol to the cell membranes, where it becomes active and presumably phosphorylates an unidentified effecter protein [1, 2] .
In rats, a ,-adrenoreceptors instead of'A ,-adenosine receptors were implicated as the initial trigger for ischemic preconditioning. The proposed sequence of events includes activation of a ,-adrenoreceptors with norepinephrine released during preconditioning episodes, interaction with G-protein and stimulation of a phospholipase-C-dependent signal transduction cascade, a pathway which may also result in translocation of protein kinase C [3, 4] . Thus, despite the differences in the receptor family initially triggered by the episodes of preconditioning ischemia/reperfusion, the suggested mechanism of preconditioning in rats and rabbits implicates translocation of protein kinase C as a final common pathway.
Virtually all evidence to date in support of this hypothesis is indirect: i.e., most previous studies have relied almost excltrsi~'elyon the use of pharmacologic agonists and antagonists of protein kinase C to mimic or block the protective effects of preconditioning. Our objective was to test the hypothesis that protein kinase C translocation plays a role in ischemic preconditioning by directly measuring the subcellular distribution jected to brief ischemia.
Methods

of PKC in rabbit hearts sub=
This study conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985) and was approved by the Institutional Care and Use Committee of the Good Samaritan Hospital (an AAALAC-accredited Institution).
Protocol I
Surgical preparation
Protocol I was designed to compare the subcellular distribution of PKC in hearts subjected to brief episodes of ischemic preconditioning versus sham-operated controls (Fig. 1) . Twelve New Zealand White rabbits (weight 2.5-3.0 kg) were anesthetized using ketamine and xylazine (100 and 20 mg\kg, respectively), administered intramuscularly. Rabbits were intubated and ventilated with room air. The chest was opened, the pericardium was Minutes Fig. 1 . Experimental protocols. Rabbits in Protocol I were randomly assigned to sham-operated and preconditioned groups. The sham-operated (SO) group underwent a 20-min waiting period, while rabbits in the preconditioned (PC) group were subjected to two 5-mirr periods of transient ischemia each followed by 5 min of reperfusion. In Protocol II rabbits were randomly assigned to sham-operated (SO), ischemic (IS) and preconditioned +ischemic (PC +1S) groups. The SO group underwent a 30-min waiting period, the IS group was subjected to 10 min of ischemia after a 20-min waiting period, and the PC+ IS group received two 5-rein episodes of preconditioning ischemia each followed by 5 min of reperfusion with a subsequent 10 min of sustained ischemia. incised and the heart was exposed. An anterolateral branch of the circumflex artery was identified and encircled with 4-O silk suture. The two ends of the suture were threaded through a piece of tubing, forming a snare that could be tightened to occlude the artery. Rabbits were randomly assigned to non-ischemic, sham-operated (SO) and preconditioned (PC) groups (n = 6 per group). The preconditioned group received two 5-rein coronary artery occlusions, each followed by 5 min of reperfusion. At the end of the last reperfusion, blue dye was injected into the heart via a left atrial catheter to define the ischemic region during a momentary coronary occlusion. The heart was immediately excised and frozen in liquid nitrogen. The non-ischemic, sham-operated group underwent a comparable 20-min waiting period following the opening of the pericardial cavity after which hearts were excised and frozen in liquid nitrogen.
PKC assay
In the first limb of the study, PKC activity was determined in two subcellular fractions: the cytosol, and remaining particulate fraction composed of the solubilized cytoplasmic membranes, nuclear and mitochondrial fragments. Details of the isolation procedure are given in Fig.  2 . Tissue samples from the ischemic area (500-600 mg) were rinsed and homogenized in a buffer containing 50 rnM Tris, pH 7.5; 1 mM EDTA; 2 mM EGTA; 10 mM benzaminidine; 0.3% &mercaptoethanol and 50~g/ml PMSF (Buffer A). One ml of buffer was used per 100 mg of tissue. Samples were homogenized in a VirTis Homogenizer, Model 23 (Baxter SP, McGaw Park, IL) at 4°C utilizing five 5-s pulses at maximum speed, each separated by 10 s. Homogenates were centrifuged for 1 h at 105000 X g using a 70.1 titanium rotor in a Beckman ultracentrifuge. The obtained fraction (the cytosolic fraction) was stored overnight in 50% glycerol at -20"C. The sediment was dispersed in a buffer containing all components described above with the addition of 0.3970Triton-X-100 (Buffer B). Samples were solubilized for 1 h by stirring at 4°C, and separated using 1 h of ultracentrifugation at 105000 X g. During this high-speed centrifugation the solubilized samples were cleared from insoluble debris and the obtained supematant (the particulate fraction) was stored overnight in 5070 glycerol at -20"C (storage of isolated PKC in so~o glycerol preserves its activity for 24 h). The purity of the fractions was verified with electron microscopy in pilot studies.
PKC activity was assayed on the next day using a commercial kit (Protein Kinase Enzyme Assay System, Amersham, Arlington Heights, IL), which utilizes a PKCspecific octapeptide (Arg-Lys-Arg-Tre-Leu-Arg-ArgLeu). This peptide represents epidermal growth factor residues, and its specificity for both conventional (calcium-dependent) and novel (calcium-independent) PKC isoforms has been documented [5] [6] [7] .
PKC fractions were diluted with buffer containing all components of Buffer A except EDTA and EGTA (Buffer C). By applying serial dilutions we found that the optimal amount of cytosolic and particulate fractions providing both high specific activity and signal intensity (i.e., net amount of counts attributed to phosphorylated substrate) corresponded to 0.325 mg of tissue. Thus, samples were diluted with Buffer C to concentrations corresponding to 0.325 mg of tissue/25 WI and incubated for 15 min at 25°C with 25 kl of 150 FM ATP plus 45 FM magnesium acetate solution containing 0.2 pCi of~zP-y-ATP (specific activity of 3000 Ci\mmol; Amersham, Arlington Heights, IL) and 25 pl of mixture containing equal parts of 12 mM calcium acetate solution, lipid solution (8 mo170Lu-phosphatidyl-L-serine plus 24~g\ml phorbol 12-myristate 13-acetate), 900 WM peptide solution and 30 mM dithiotreitol solution. All reagents were prepared in 50 mM Tris/HCl buffer (pH 7.5). The total volume of the incubation mixture was 75~1. Reaction was terminated by adding 100 pl of 1.5?I0orthophosphoric acid. Blanks for calcium-phospholipid-independent PKC activity were assayed by substituting calcium acetate and lipid solutions with 12 rnM EGTA and 50 mM Tris\HCl (pH 7.5) solutions, respectively. Blanks for endogenous phosphorylation were assayed by eliminating the peptide solution from the assay system and substituting it with 50 mM Tris/HCl, pH 7.5. Separation of peptide-bound radioactivity was performed by using SpinZyme Basic Separation Unit (Pierce, Rockford, IL). This unit consists of a 1.5 ml microcentrifuge tube and a receptacle with a phosphocellulose filter. The reaction mixture (50 pl) was centrifuged through the filter and washed with 75 mM phosphoric acid. The receptacle was placed into a scintillation vial and radioactivity bound to the phosphocellulose filter was counted in a Beckman liquid scintillation counter. Blanks for both calcium-phospholipid-independent and endogenous phosphorylation were negligible (comprised 2.1 + 0.6 and 2.4+ 1.0% of the total PKC activity, respectively) and thus were not subtracted from the total PKC activity. PKC activity was expressed as pmol/min/g wet tissue.
Protocol II
Surgical preparation
Our objective in Protocol II was to determine whether ischemic preconditioning may lead to PKC translocation during the early minutes of subsequent 'sustained' coronary occlusion (Fig. 1) . Eighteen New Zealand White rabbits were subjected to the same surgical procedure as in Protocol I. After opening the pericardial cavity, the rabbits were randomly assigned to a non-ishemic, sham-operated (SO) group, an ischemic (IS) group and a preconditioning + ischemic (PC + IS) group. After receiving two 5-rein episodes of ischemia each followed by 5 min of reperfusion, rabbits in the PC + IS group were subjected to 10 min of sustained coronary occlusion. Rabbits in the IS group, after a 20-min waiting period, received 10 min of sustained ischemia without preconditioning, while animals in the SO group received a 30-min waiting period. The ischemic area in IS and PC + IS groups was delineated with blue dye as in Protocol I and hearts were quickly excised and frozen in liquid nitrogen
PKC assay
To obtain greater subcellular resolution, Protocol II was modified to permit measurement of PKC in 3 (rather than 2) subcellular fractions: the cytosol, the nuclei, and the cell membranes. The isolation procedure is presented in Fig. 3 . Tissue samples from the ischemic area (500-600 mg) were homogenized in Buffer A using a Polytron homogenizer (Model 10-35, Brinkman, Westbuny, NY) at 4"C. Four 5-s pulses at half-maximum speed each separated by 10 s were applied. Homogenates were centrifuged at 2000 X g for 15 min and the supematant (containing cytosol and membrane fractions) was spun at 105000X g for 1 h. The 105000X g supernatant from this step was stored in 50~o glycerol as the cytosolic fraction. Sediment from this 105000 X g spin (containing the membrane fraction) was stirred in Triton-X-1OOcontaining buffer (Buffer B) for 1 h at 4°C and then centrifuged at 105000 X g. This centrifugation removes all debris from the membrane fraction that was not solubilized in Triton-X-100. Supernatant from this step was stored in 50% glycerol as the membrane fraction. The 2000X g sediment (nuclear fraction) was washed in Buffer C and centrifuged at 2000 X g for 15 min. The resulting sediment was dispersed in Buffer C and spun at 105000 X g for 1 h. This centrifugation makes the sediment more compact and expels everything trapped by the nuclear fraction after the homogenate was washed at 2000X g. Sediment from this step was suspended in Buffer B (Triton-X-100 containing buffer) and was continuously stirred at 4°C for 1 h and centrifuged (105 000 X g, 1 h). This centrifugation removes all debris from the nuclear fraction that was not solubilized in Triton-X-100. The resultant supematant (nuclear fraction) was stored in 50% glycerol at -20°C. Electron microscopy was used to verify purity of the fractions. PKC assay was performed as described for Protocol I. Aliquots providing high specific activity and signal intensity corresponded to 0.325 mg of tissue for the cytosolic fraction and 1.5 mg of tissue for nuclear and membrane fractions. Results from pilot studies showed that in this concentration range, similar activities were obtained by using DEAE-Sephacel columns and by employing the current dilution method. Based on these results, the dilution method was employed. Samples were diluted with Buffer C to the concentrations corresponding to 0.325 mg of tissue/25 pl for the cytosolic fraction and 1.5 mg of tissue\25 pl for the nuclear and membrane fractions. PKC was assayed by using the Amersham kit and SpinZyme Basic Separation Unit. Radioactivity was measured in a Beckman liquid scintillation counter. Blanks for calciumphospholipid-independent PKC activity and endogenous phosphorylation comprised 4.5 + 0.9 and 3.2 + 0.7% of the total PKC activity respectively and were not subtracted from the total PKC activity.
Our assay system contains all co-factors that are necessary to activate protein kinase C molecules present in the isolated subcellular fractions. This implies that an in vivo PKC activation, not followed by its translocation, cannot be measured. However, this method reliably measures PKC translocation and changes in its subcellular distribution. Thus, the term 'PKC activity', used to describe PKC assay results, implies the amount of PKC present in each fraction and activated during the assay procedure.
Since we isolated subcellular fractions from a preweighed amount of tissue, protein kinase C activity was expressed as pmol/min/g wet tissue. Consistency of protein yield in each subcellular fraction was confirmed using Sigma Diagnostics Kit (Sigma Chemical Co., St. Louis, MO; Procedure No. 690).
Statistical unalysis
Statistical analysis was performed separately for each protocol using two-factor ANOVA (for treatment and fraction).
Results
protocol I
There was no difference in the subcellular distribution of PKC in hearts sampled immediately after the last episode of preconditioning ischemia/reperfusion in the PC group when compared with the SO group. PKC activity comprised 4749 +-484 and 5437 + 520 pmol/min/g in the cytosolic fraction and 2781 t 300 and 2492 + 269 pmol/min/g in the particulate fraction in the SO and PC groups, respectively; P = NS (Fig. 4) . Protein yield was comparable in both groups and comprised 48.9 + 1.8 and 15.2 + 0.9 mg/g wet tissue in the cytosol and particulate fractions in the SO group and 46.1~2.4 and 15.4 + 1.3 mg\g wet tissue in the cytosolic and particulate fractions in the PC group (P= NS).
Protocol II
No differences were observed in the PKC subcellular distribution among the SO, IS and PC + IS groups. PKC activity comprised 4435~290, 4311 +-161 and 4227 + 439 pmol/min/g in the cytosol fraction, 638 + 57, 934+ 96 and 951 f 68 pmol/min/g tissue in the nuclear fraction, and 582 + 25, 768 + 54 and 680146 pmol/min/g tissue in the membrane fraction in the SO, IS and PC + IS groups, respectively (P= NS). Thus, there was no difference in the subcellular distribution of PKC between pre- conditioned and non-precondiotioned hearts sampled following 10 min of sustained coronary occlusion (Fig. 5) . Protein yield was 55.1~4.3, 13.7~1.0 and 11.3 + 1.5 mg/g wet tissue in the SO group in the cytosol, nuclear and membrane fractions, respectively, with no changes in its content between the studied groups ( P = NS).
Discussion
In this study, PKC translocation was, for the first time, directly measured in in-vivo rabbit hearts subjected to ischemic preconditioning. Our data indicate that in the rabbit model, brief episodes of ischemic preconditioning known to reduce infarct size [8] did not cause PKC translocation.
Specificity of the a,ssay
In a recently published study we reported that intramyocardial injections of phorbol myristate acetate caused a marked redistribution of PKC activity in the dog heart. Using the same assay as in the current study, we found that PKC in the cytosolic and particulate fractions averaged 64 vs. 36Y0and 34 vs. 66% in control vs. PMA-treated hearts, respectively [9] . These data indicate that our technique readily detects PKC translocation in vivo.
The peptide used in our study to determine PKC activity (Arg-Lys-Arg-Tre-Leu-Arg-Arg-Leu ) was shown to be a specific substrate for both conventional and novel isoforms (PKCa, PKC5 and PKCe) [6, 7] . To date, four PKC isoforms (a-, 8-, e-and~-) have been identified in neonatal hearts. However, in adult ventricular myocytes, only two isoforms (8-and e-), both calcium-independent, have been detected. Conventional PKCa. and atypical PKC~, both showing low immunoreactivity, were detected only in extracts from adult heart (but not from adult cardiomyocytes) and were suggested to be attributed to noncardiac cells in the heart [10, 11] . Thus, the specific substrate used in our study is capable of detecting all isoforms identified to date in adult cardiomyocytes.
Comparison with previous studies
There is evidence that in the isolated heart model, global ischemia can trigger PKC translocation. For example, Strasser et al, [12] showed that 10 min of global ischemia in the isolated perfused rat heart caused PKC translocation from cytosol to the particulate fraction. Their results were obtained by directly measuring PKC activity in both cytosolic and particulate fractions. Based largely on these biochemical data, the PKC hypothesis of preconditioning was formulated. In fact we recently found that PKC translocation in globally ischemic heart can be demonstrated even earlier; i.e., at 2 min after the ischemic insult (data accepted for presentation at 69th Scientific Sessions of AHA).
In indirect support of this theory, Liu et al. [1] and Ytrehus et al. [2] reported that PKC inhibitors (staurosporine and polymyxin B) effectively blocked the protective effect of ischemic preconditioning in rabbit heart in vivo, while the PKC activator phorbol myristate acetate (PMA), was able to mimic ischemic preconditioning in the isolated rabbit heart. Similarly, in the rat model Li and Kloner [13] and Mitchell et al. [4] demonstrated that PKC inhibitors calphostin C, staurosporine and chelerythrine attenuated the protective effect of the ischemic preconditioning in vivo and in vitro. Therefore the authors concluded that receptor-mediated translocation of PKC is a crucial step in the mechanism of the ischemic preconditioning. However, with the exception of one study showing qualitative histologic evidence of PKC translocation to cell membranes with brief global ischemia in isolated rat hearts [4] no direct and quantitative measurements of the subcellular distribution of PKC were performed in response to either preconditioning ischemia, PKC agonists or antagonists. Thus, it is not clear whether the protective effect of ischemic preconditioning and its attenuation in the presence of PKC inhibitors are truly due to the changes in PKC subcellular distribution. To date, we have insufficient information to resolve this apparent discrepancy between the pharmacologic evidence for the role of PKC in preconditioning versus the biochemical evidence arguing against PKC translocation with brief preconditioning ischemia. However, it is possible that other, yet unknown, effects of PKC inhibitors and/or their solvents may contribute to the attenuation of the ischemic preconditioning [14] .
It also cannot be ruled out that PKC activation during preconditioning episodes, not followed by its translocation, may play a role in the protective effect of ischemic preconditioning. However, no method has yet been developed that would allow quantitative measurement of the in vivo PKC activation and, thus, no data in support of its possible implication in ischemic preconditioning are currently available. Importantly, the PKC theory of ischemic preconditioning we sought to test proposes that the enzyme is translocated during brief episodes of preconditioning ischemia, and thus mandates a change in the enzyme subcellular distribution in preconditioned hearts [1, 2, 4] . In our experiments we did not observe any difference in PKC'S subcellular distribution between matched groups of control and preconditioned hearts.
The present study and recently published data [9] indicate that one or more 5-rein episodes of brief transient ischemia failed to alter the subcellular distribution of PKC at 10 min into sustained ischemia in both rabbit and dog ischemia models. In contrast, there is no doubt that one or more 5-rein episodes of brief ischemia effectively confer protection against subsequent sustained coronary occlusion. Using the same preconditioning regimen in rabbits, Hale et al. showed that infarct size was reduced by 43% following a 40-min sustained occlusion [8] . Thus, our direct measurements of PKC subcellular distribution fail to support the hypothesis that its translocation may play a crucial role in ischemic preconditioning in the rabbit model. However, it cannot be ruled out that other signal transduction proteins (i.e., tyrosine protein kinases) may be involved in ischemic preconditioning and underlie the ability of cardiac tissue to 'remember' previous episodes of preconditioning ischemia and to respond with increased resistance to subsequent ischemia/reperfusion.
Critique of the method
The enzyme assay system employed in our study is based upon the transfer of the y-phosphate group from y-32P-adenosine triphosphate to a protein-kinase-C-specific peptide. The assay system contains all factors that are necessay to activate the enzyme: i.e., calcium ions and lipids. This means that protein kinase C activity in the assay is activated very close to its maximum and the signal is proportional to the amount of the enzyme present in the sample. Thus, only PKC translocation can be determined with this radioactive technique; the possibility of activation of PKC with ischemic preconditioning (not followed by enzyme translocation) cannot be ruled out.
A second limitation of this radioactive technique is that it is unable to discern individual PKC isoforms. In order to distinguish individual isoforms, an immunoblot analysis is required. However, the immunoblotting technique provides no information regarding the functional activity of the isoforms, and therefore does not address the crucial question of whether the isoforms can phosphorylate the unknown target protein. The proportion of inactive PKC isoforms already present in particulate fractions cannot be estimated before the immunoblotting procedure and may create difficulties in interpreting immunoreactivity data [10] . Had we observed even a trend toward a difference in the overall subcellular distribution of PKC with preconditioning we would have continued with detailed cell-and isoform-specific methods. However, we found no evidence to support the hypothesis that translocation of PKC to cell membranes plays an important role in ischemic preconditioning.
